Celgene Acquires Abraxis In $2.9 Billion Deal
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
313
InterMune Shares Rise On FDA Panel Recommendation
The recommendation caused a 64 percent jump in InterMune stock prices and fueled speculation that the Brisbane, Calif.-based company is ripe for acquisition.
NeoPharm to Investigate Treatment for Deadly Lung Disease
The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year.
FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
Sen. Kennedy Death Puts Focus On Brain Cancer
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
NeoPharm Tipped As Stock to Watch
NeoPharm, a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha.